Case 6: 47-Year-Old Male With Leukocytosis, Anemia, and Splenomegaly

Video

Sa Wang, MD, presents the case of a 47-year-old male with leukocytosis, anemia, and splenomegaly.

Sa Wang, MD: I’m moving on to the last case. This 47-year-old patient presents with leukocytosis, anemia, splenomegaly. WBC [white blood cell count] was 57,000. It was 21% monocytes, anemic, and platelets were actually elevated. This is the bone marrow biopsy. We do have a little bit of thickening of the bone, but what you notice in this part is there are a lot of megakaryocytes; on the higher part you see megakaryocytes are very small and dysplastic. These are megakaryocytes, so we know we are dealing with very hypercellular, with dysplastic karyocytes. This patient with monocytosis, immediately we’re thinking, could this be CMML [chronic myelomonocytic leukemia]? Another thing you notice is that we do have a slight increase in eosinophils in this patient. But here, in some areas it looks like there are a little bit of spindle cells. However, when you have a diagnosis, you say, “Wow, I already got my diagnosis of CMML.” Then, CMML can have liver fibrosis. It’s nothing surprising. In this case, you can see here on the bone marrow aspirate smear, we have blasts. We have myeloid precursor monocytes. When we did the CD34, the patient does have CD34 clustering, which further supports the diagnosis of myeloid neoplasm, and also CD34 was about 5%. The diagnosis was CMML. We actually did flow cytometry. You see the CD34 cells, they had aberrancy of CD56 expression, have the aberrant CD5 expression, and also aberrant CD34 and CD117. The monocytes were 15.2%. Everything goes very well with CMML, so the diagnosis was CMML.

About 70% of patients with CMML have a normal karyotype, but the NGS [next-generation sequencing] came back, and we had a KIT mutation and ASXL1 and U2AF1. The KIT mutation burden was very high at 41%. We actually went back to look for the mast cells in this case. When we did CD117, you can see the mast cells were very focal. I amplified this, with the higher power you do see the cells, the spindle cells, but it was completely ignored. No one can blame anyone for missing these small mast cell aggregates. You can see, as I said, when you see a mast cell in the future, in the surrounding, you see some eosinophils on the edge. It’s very common to see mast cells. The rest of the mast cells are very scattered, few spindles, but that is the whole bone marrow biopsy. We only have this little bit of mast cell aggregate. I go back to this, according to Dr…you’re supposed to call this SM [systemic mastocytosis], associated with hematologic malignancy with underlying disease and CMML. However, we all know this is probably a dominant disease, it’s a chronic myelomonocytic leukemia with very focal mast cell. Proliferation or differentiation, both are quite clear of SM. With SM, you have more than 15 cells in aggregate, and they are mostly spindly, and also you have KIT mutation with…criteria. We also had flow cytometry, this is when the patient came back…you can see they are CD30 positive, CD25 positive, and no CD2.

I think this case raises a number of questions. This is apparently KIT-mutated myeloid neoplasm. Is the presence of the small mast cell aggregate relevant in this case? If we call this according to the WHO [World Health Organization] criteria, how do you assess the C findings because underlying neoplasm in CMML can cause the anemia? Another question is, concerning this patient, are they going to respond to this mast cell inhibitor like avapritinib? In this case, if the mast cell infiltrate is more than 30%, how is that going to change your assessment and management? I think this question, as a pathologist, I raise for you the clinicians.

Transcript edited for clarity.

Related Videos
Video 16 - "Trajectory of Evolving HCC Treatment Landscape"
Video 15 - "REGONEXT Study: Driving Second-line HCC Treatment Strategy"
A panel of 4 experts on colorectal cancer
A panel of 4 experts on colorectal cancer
A panel of 5 experts on renal cell carcinoma
Chandler H. Park, MD, an expert on renal cell carcinoma
Video 8 - "Post-Thyroidectomy Management: Thyroid Hormone Replacement and TSH Suppression"
Video 7 - "The Importance of Thyroidectomy in DTC Patient Care"
Related Content
Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment

Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment

September 15th 2021
Article